The Institute for Medical Research (IMR) will host a Scientific Seminar on March 12 at 11:00. The Seminar will bring together researchers around two current topics in pharmacology and medicinal chemistry, with guest lectures from the Faculty of Pharmacy, University of Belgrade.
Dr. Milan Beljkaš will present research focused on the development of dual HDAC/ROCK inhibitors as a potential therapeutic strategy for aggressive malignancies, including pancreatic ductal adenocarcinoma and triple-negative breast cancer. The lecture will outline an integrated approach combining in silico methods—molecular docking, machine learning, and 3D-QSAR—with experimental in vitro validation of novel antitumor compounds.
Katarina Sićović will present findings from a preclinical study examining the therapeutic potential of semaglutide in a model of chronic migraine. Particular focus will be placed on pain hypersensitivity, cognitive deficits, and the role of central opioidergic mechanisms in the pharmacological response.
IMR Scientific Seminars are intended to present current research and encourage scientific exchange among researchers from different areas of biomedical science.
